Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of AL amyloidosis.~* Evidence of a monoclonal light chain at serum and/or urine immunofixation electrophoresis.~* Elevated circulating free light chain (of the type identified by immunofixation) above the upper limit of the normal range and abnormal kappa/lambda ratio.~* Previously treated and requiring further treatment.~* Symptomatic organ involvement.~* Bone marrow plasma cell \<30%.~* Echocardiographic ejection fraction \>40%.~* Troponin I \<0.1 ng/mL.~* Hemoglobin \>10 g/dL.~* Absolute neutrophil count \>1500/uL.~* Platelet count \>140000/uL.~* Total bilirubin \<2.5 mg/dL.~* Alkaline phosphatase \<4 x upper reference limit (u.r.l.).~* ALT \<3 x u.r.l..~* Glomerular filtration rate \>30 mL/min.~* Performance status ECOG 1-3.~* Female subjects of childbearing potential must have two negative pregnancy tests prior to starting study drug.~Exclusion Criteria:~* Prior treatment with the association of cyclophosphamide, lenalidomide and dexamethasone or with lenalidomide.~* Requirement for other concomitant chemotherapy, immunotherapy or radiotherapy, or any investigational ancillary therapy.~* Presence of other active malignancies, with the exception of nonmelanoma skin cancer, cervical cancer, treated early-stage prostate cancer provided that prostate specific antigen is within normal limits.~* Clinically overt multiple myeloma.~* Uncontrolled infection.~* New York Heart Association (NYHA) class 4 heart failure.~* Enzyme documented myocardial infarction within 6 months before enrollment.~* Grade 2 or 3 atrioventricular block (Mobitz type I is permitted).~* Repetitive ventricular arrhythmias at 24 h Holter electrocardiogram in spite of treatment with amiodarone.~* Supine systolic blood pressure \<90 mmHg, or symptomatic orthostatic hypotension, or a decrease in systolic blood pressure on standing of \>20 mmHg in spite of being treated for orthostatic hypotension.~* Prior history of thrombosis or venous thromboembolism or pulmonary embolism. Prior diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency.~* Indication to receive clopidogrel, ticlopidine or warfarin.~* Factor X level \<20%.~* Poorly controlled diabetes mellitus (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months).~* Previous or ongoing psychiatric illness (with the exclusion of reactive depression).~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The participants receive up to 9 28-day cycles of~* cyclophosphamide: 500 mg orally on days 1, 8, 15;~* lenalidomide: 15 mg orally on days 1-21;~* dexamethasone: 40 mg orally on days on days 1, 8, 15, 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).